- Naranj Research Desk
- 🇸🇦 Saudi Stock Market
- 🇺🇸 USA Stock Market
NVO — NYSE —
Current RSI of this stock is 68.65, which indicates the strength of buyers.
Increasing ADX value above 20, indicated the strength of the trend, thereby uptrending ADX confirms the bullish or bearish supportive decisions. Along with the rising ADX, and the +DI is above (or crossing) -DI, indicates the long trades should be favoured.
MACD line has just crossed the signal line from the below, generates bullish signal.
Based on our swing trading signals for US stocks, Novo Nordisk stock price target will be USD 150 - USD 152 in the next 14-15 trading sessions.
Novo Nordisk A/S, along with its subsidiaries, is involved in the research and development, manufacturing, and distribution of pharmaceutical products across various regions including Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and globally. The company operates through two main segments, namely Diabetes and Obesity Care, and Rare Disease. Novo Nordisk A/S also offers a range of medical devices such as insulin pens, growth hormone pens, and injection needles. Moreover, the company provides innovative solutions for diabetes management, including smart insulin pens and Dose Check, an application for insulin dose guidance. Additionally, Novo Nordisk A/S has a partnership with Aspen Pharmaceuticals for the production of insulin products. Established in 1923, the company is headquartered in Bagsvaerd, Denmark.
NVO — NYSE —
Current RSI of this stock is 68.65, which indicates the strength of buyers.
Increasing ADX value above 20, indicated the strength of the trend, thereby uptrending ADX confirms the bullish or bearish supportive decisions. Along with the rising ADX, and the +DI is above (or crossing) -DI, indicates the long trades should be favoured.
MACD line has just crossed the signal line from the below, generates bullish signal.
Based on our swing trading signals for US stocks, Novo Nordisk stock price target will be USD 150 - USD 152 in the next 14-15 trading sessions.
Arijit Banerjee CMT CFTe is a seasoned expert in the financial industry, boasting decades of experience in trading, investment, and wealth management. As the founder and chief strategist of Naranj Capital, he’s built a reputation for providing insightful research analysis to guide investment decisions.
Arijit’s credentials are impressive, holding both the Chartered Market Technician (CMT) and Certified Financial Technician (CFTe) designations. These certifications demonstrate his expertise in technical analysis and financial markets.
Through Naranj Capital, Arijit shares his market insights and research analysis, offering actionable advice for investors. His work is featured on platforms like TradingView, where he publishes detailed analysis and recommendations.
If you’re interested in learning more about Arijit’s work or Naranj Capital’s services, you can reach out to them directly through their website
